(Updated November 2019)
ACCRF has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. Patients may search on their own for recruiting ACC clinical trials on the ClinicalTrials.gov website.
The clinical trials are broken down into three categories.
- The first table lists studies that are recruiting any and all ACC patients (usually phase II clinical trials).
- The second table lists studies appropriate for ACC patients whose tumors have been profiled and found to have activating alterations in NOTCH genes (either phase I or II clinical trials).
- The third table includes clinical trials that incorporate tumor profiling prior to selecting a drug (“basket studies”).
In all cases, patients should consult with their physicians to discuss the appropriate course of action.
Not all clinical trials have similarly strong scientific rationales for why the drugs should be effective in ACC. The most promising studies will involve drugs that (1) target the known mechanisms of action that drive ACC progression, (2) demonstrate activity in preclinical models of ACC, and (3) have reports of clinical benefit in an ACC patient from a case study or Phase I clinical trial. To assist patients in appraising each clinical trial, we indicate whether the evidence supporting the scientific rationale is strong, solid or fair. This assessment is based on the underlying scientific rationale, and does not mean that a particular trial is better or worse for any given patient, and should be considered along with his or her physician.
The table below lists clinical trials that currently are recruiting ACC patients in particular or salivary gland cancer patients. Unless otherwise noted, these studies are for only ACC patients with recurrent or metastatic disease. Links are provided to descriptions of the drugs as well as the www.ClinicalTrials.gov summary of each study.
Clinical Trials for All ACC Patients
Compound Targets Sponsor Locations Scientific Rationale Info Link Contact All-trans Retinoic Acid
Boston, MA, USA Strong View Glenn Hanna, MD
Jong Chul Park, MD
MYB vaccine and Tislelizumab MYB & PD-1 Immunotherapy Peter MacCallum Cancer Centre Melbourne, Australia Strong View Jayesh Desai
+61 38559 7810
APG-115 with or without Carboplatin MDM2 University of Michigan Ann Arbor, MI, USA Strong View Paul L Swiecicki, MD 734-647-1017 firstname.lastname@example.org
Ryan Drzewicki email@example.com
Axitinib and Avelumab VEGFR, PDGFR, KIT and PD-L1 Immunotherapy MD Anderson Houston, TX, USA Strong View Renata Ferrarotto, MD
Pembrolizumab and Docetaxel PD-1 Immunotherapy University of Chicago Chicago, IL, USA Solid View Alexander Pearson, MD, PhD
Nivolumab and Ipilimumab and Radiation PD-1
University of Washington Seattle, WA, USA Solid View Susan Masterson
Chidamide HDAC Chinese Academy of Medical Sciences Beijing, China Solid View Mei Dong
Chidamide and Cisplatin HDAC Fudan University Shanghai, China Solid View Kai Xue, MD
Apatinib and Proton Radiation (for inoperable or residual ACC) VEGFR Shanghai Proton and Heavy Ion Center Shanghai, China Strong View Lin Kong, MD firstname.lastname@example.org
Jiyi Hu, MD email@example.com
Approximately 25% of metastatic ACC patients have tumors with activating alterations in the NOTCH pathway (primarily in the NOTCH1 gene). These tumors behave more aggressively. Patients for whom tumor profiling has identified a NOTCH pathway alteration may wish to discuss the following studies with their physicians:
Clinical Trials for ACC Patients with Activating NOTCH Alterations
Compound Targets Sponsor Locations Scientific Rationale Info Link Contact AL101 NOTCH Ayala Pharmaceuticals Calgary, Alberta, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Boston, MA, USA
Houston, TX, USA
Miami, FL, USA
New York, NY, USA
Tampa, FL, USA
Seattle, WA, USA
Strong View Accuracy@ayalapharma.com CB-103 NOTCH Cellestia Pharmaceuticals Amsterdam, Netherlands
Strong View Pavel Pisa, MD
Historically, clinical trials involved only one or two treatments. Some newer trials are incorporating tumor profiling to direct patients to many more potential treatments within the same study. These “basket trials” try to match targeted drugs to genomic alterations in each patient’s particular tumor. Some of these trials profile the patient’s tumor as party of the study (NCI-MATCH) while others will suggest treatment decisions based on existing tumor profiling reports (ASCO TAPUR). The clinical trials listed below are not specifically for ACC patients, but may be worth considering in consultation with a knowledgeable physician.
“Basket” Clinical Trials Incorporating Tumor Profiling
Compound Targets Sponsor Locations Scientific Rationale Info Link Contact NCI-MATCH Multiple targets National Cancer Institute Over 1,000 locations in USA Solid View View Info Link for details on each site NCI-DART
(Nivolumab with Ipilimumab
for NCI-MATCH patients with rare tumors without targetable alterations)
Multiple targets National Cancer Institute Over 600 locations in USA Solid View View Info Link for details on each site ASCO TAPUR Multiple targets American Society of Clinical Oncology Over 20 locations in USA Solid View Pam Mangat, MS
Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
(for salivary gland cancer patients, including ACC; only Canadian patients are eligible)
Multiple targets University Health Network, Toronto Toronto, Ontario, Canada Solid View Aaron Hanson, MD
Download Selected Clinical Trials – Currently Open (Updated November 2019)